Clinical trial researches combination drug therapy for kidney cancer

Female doctor and female patient

Image credit: Canva

Renal cell cancer, also called kidney cancer, is a disease in which malignant cancer cells form in the tubules of the kidney. Some kidney tumors do not respond well to current treatments. A clinical trial led by Ramaprasad Srinivasan, M.D., Ph.D., Senior Investigator in the Urologic Oncology Branch, is researching a combination drug therapy for adults with clear cell renal cell carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC).

The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.

For more information, please contact Brooke Augustine at (240) 858-3197 or identifier: NCT05665361

NCI Protocol ID: 000666

Official Title: A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Posted on Wed, 09/20/2023